IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, will present initial data at their 10 ...

A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrates encouraging safety and efficacy results in ...

A first-in-human Phase I study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate (ADC), demonstrated manageable safety and early signs of anti-tumor activity in ...

Cuba’s Soberana 2 COVID-19 Vaccine – What is conjugate vaccine and how does it work? Cuba's Soberana 02 vaccine is a conjugate vaccine which carries part of the spike protein from the virus ...

OBI is a clinical stage global oncology company that is headquartered in Taiwan and established in 2002. Its mission, together with its wholly owned subsidiary OBI Pharma USA, Inc., is to develop ...

Results from the IDeate-Lung01 phase 2 trial showed that ifinatamab deruxtecan demonstrated clinically meaningful response rates in patients with ...

Enveric's Akos Biosciences licensed its cannabinoid-COX-2 conjugate technology to Restoration Biologics for joint disease treatments, including osteoarthritis.

Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting ...

A first-in-human Phase 1 study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate (ADC), demonstrated manageable safety and early signs of anti-tumor activity in ...